4//SEC Filing
NUSSDORF GLENN H 4
Accession 0002064832-25-000013
CIK 0001661181other
Filed
Nov 2, 7:00 PM ET
Accepted
Nov 3, 5:25 PM ET
Size
14.2 KB
Accession
0002064832-25-000013
Insider Transaction Report
Form 4
NUSSDORF GLENN H
Director10% Owner
Transactions
- Sale
Class A Common Stock
2025-06-09$3.50/sh−4,156$14,547→ 354,339 total(indirect: By Trust) - Purchase
Class A Common Stock
2025-05-15$2.99/sh+107,494$320,999→ 358,495 total(indirect: By Trust) - Purchase
Class A Common Stock
2025-05-14$3.09/sh+251,001$775,041→ 251,001 total(indirect: By Trust) - Sale
Class A Common Stock
2025-06-10$3.56/sh−18,620$66,256→ 335,719 total(indirect: By Trust)
Holdings
- 3,065,591
Class A Common Stock
- 918,680(indirect: By Trust)
Class A Common Stock
- 7,928,570(indirect: By GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016)
Class A Common Stock
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.00 to $3.10, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.9725 to $3.00, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.50 to $3.505, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.59, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
- [F5]The reporting person's sale of an aggregate of 22,776 shares of the issuer's Class A common stock on June 9, 2025 and June 10, 2025 reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, with the reporting person's purchase of 22,776 shares of the issuer's Class A common stock on May 15, 2025. The reporting person has paid to the issuer an amount equal to $13,285.24, representing the full amount of the profit realized in connection with the short-swing transaction ($12,971.78) plus interest at the rate of 6% per annum through the date of payment ($313.46).
Issuer
Organogenesis Holdings Inc.
CIK 0001661181
Entity typeother
Related Parties
1- filerCIK 0001244191
Filing Metadata
- Form type
- 4
- Filed
- Nov 2, 7:00 PM ET
- Accepted
- Nov 3, 5:25 PM ET
- Size
- 14.2 KB